No headlines found.
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Globe Newswire (Wed, 18-Mar 5:31 PM ET)
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Globe Newswire (Wed, 18-Feb 8:00 AM ET)
Globe Newswire (Mon, 26-Jan 7:00 AM ET)
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.
Marker Therapeutics trades on the NASDAQ stock market under the symbol MRKR.
As of April 17, 2026, MRKR stock price climbed to $1.66 with 177,386 million shares trading.
MRKR has a beta of 1.70, meaning it tends to be more sensitive to market movements. MRKR has a correlation of 0.08 to the broad based SPY ETF.
MRKR has a market cap of $27.68 million. This is considered a Sub-Micro Cap stock.
Last quarter Marker Therapeutics reported $1 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $453,800 and exceeded earnings estimates by $.10.
In the last 3 years, MRKR traded as high as $9.68 and as low as $.76.
The top ETF exchange traded funds that MRKR belongs to (by Net Assets): VTI, VXF.
MRKR has outperformed the market in the last year with a price return of +44.3% while the SPY ETF gained +36.3%. However, in the short term, MRKR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.3% vs +2.9% return in SPY. But in the last 2 weeks, MRKR shares have fared better than the market returning +25.8% compared to SPY +8.3%.
MRKR support price is $1.51 and resistance is $1.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRKR shares will trade within this expected range on the day.